Ask whether a drug works before worrying about what it costs

16 July 2019 - Last week was supposed to be a turning point for drug price transparency.  ...

Read more →

Do cancer treatments have option value? Real‐world evidence from metastatic melanoma

24 June 2019 - A change in the expectations about future treatments may change the option value of a current ...

Read more →

It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...

Read more →

Novel approaches to value assessment within the cost-effectiveness framework

20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...

Read more →

Drug pricing should reflect value, not recoupment of investment

20 June 2019 - The other day I was reading a piece on reframing the conversation on drug pricing. I ...

Read more →

Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price

18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...

Read more →

New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?

12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...

Read more →

Systematic literature review calls economic impact of switching to biosimilars "uncertain"

10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...

Read more →

The $2.1 million question: what are the medical, ethical implications of the world's priciest drug?

10 June 2019 - With last month’s FDA approval, Zolgensma became the world’s most expensive medication.  ...

Read more →

Paying for CAR-T therapy amidst limited health system resources

3 June 2019 - CAR-T is paving a new path toward achieving access and reimbursement within limited health-system resources. How do ...

Read more →

Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000

3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...

Read more →

Cost effectiveness analysis in the context of US commercial health insurance

29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...

Read more →

ICER comments on the FDA approval of Zolgensma for the treatment of spinal muscular atrophy

24 May 2019 - ICER’s update reflects the gene therapy’s new clinical data and FDA label. ...

Read more →

Extending VBP models into Medicaid drug purchasing: challenges and opportunities

22 May 2019 - Over the past decade, both public and private payers have increasingly sought to develop payment policies that ...

Read more →

Official Information Act response: adrenaline auto-injector cost utility analysis

20 May 2019 - PHARMAC responds to a request for any cost utility analyses performed by PHARMAC in relation to ...

Read more →